The science of genetic medicine mostly works. Making enough of it, reliably, is the harder problem investors are now funding.
Cell and gene therapy has spent the last decade proving the science works. It's spent the last two years proving that manufacturing it at scale is the much harder, much less glamorous problem, and that's increasingly where the capital is concentrating.
A manufacturing bottleneck becomes its own funding category
Cell and gene therapy platforms, including ElevateBio, Cellares, ArsenalBio, Kriya, AvenCell, Capstan, and Chime Biologics, have together raised roughly $4.2B, according to New Market Pitch's biotechnology funding tracker. Separately, Flagship Pioneering's newest venture, Serif Biomedicines, launched with $50M to develop what it calls "modified DNA" medicines, designed to combine the strengths of gene therapy, mRNA, and small-interfering RNA approaches in a single modality rather than picking one.
The federal government has also stepped in specifically on the manufacturing side. ARPA-H's new GIVE program is funding distributed, individualized biomanufacturing for genetic medicines, aiming to get a genetic treatment ready to dose within a week of diagnosis, a direct acknowledgment that centralized manufacturing is the actual chokepoint slowing the field down, not the underlying biology.
Gene editing companies rank second in biotechnology funding with $2.288B raised across just 17 deals, a 13.48% share of capital that shows sustained institutional interest even as the broader cell and gene therapy segment remains stuck near a multi-year funding plateau.
The science outran the supply chain
For companies like ElevateBio and Cellares, the pitch isn't a new therapy, it's the infrastructure that lets other companies' therapies actually reach patients at scale. That's a meaningfully different, and arguably more durable, business than betting on any single genetic medicine's clinical trial outcome. It also explains why capital is flowing into "tools and platforms" alongside therapeutics themselves.
Cell and gene therapy makers overall are on pace to raise about $2 billion in 2026, similar to most years since 2022, according to BioPharma Dive, a multi-year plateau that stands in sharp contrast to the $13.168B flowing into therapeutics discovery platforms more broadly. The gap between "the science works" and "the manufacturing scales" is precisely where that plateau sits.
Whether ARPA-H's bet pays off before private capital loses patience
Watch whether ARPA-H's GIVE program produces a genuinely viable distributed manufacturing model, since that would be the clearest signal yet that the bottleneck is solvable rather than structural. Also watch whether Serif Biomedicines' "modified DNA" combination approach, betting that blending modalities beats picking one, becomes a template other well-funded platforms attempt to replicate, or whether it turns out combining approaches multiplies manufacturing complexity rather than solving it.
